MEG3 and liver cancer: However, MEG3 plus β-catenin did not significantly alter the PCNA positive rate of liver cancer cells (49.13 ± 12.38% versus 41.33 ± 7.88%, P = 0.237289 >0.05) (Fig. 12c).